Almirall - Siste nytt https://www.mynewsdesk.com/no/almirall-ab Mynewsdesk RSS - pressemeldinger, nyheter og blogginnlegg Almirall - Siste nytt https://www.mynewsdesk.com/no/almirall-ab https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 no 15 Den 7-9 mai 2025 er Almirall Diamant-sponsor under NCDV, Nordic Congress of Dermatology and Venereology, i Helsinki Wed, 07 May 2025 08:00:00 +0200 Almirall er Diamant-sponsor under NCDV, den 7-9 mai 2025 i Helsinki https://www.mynewsdesk.com/no/almirall-ab/news/den-7-9-mai-2025-er-almirall-diamant-sponsor-under-ncdv-nordic-congress-of-dermatology-and-venereology-i-helsinki-497001?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/news/den-7-9-mai-2025-er-almirall-diamant-sponsor-under-ncdv-nordic-congress-of-dermatology-and-venereology-i-helsinki-497001?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB Almirall’s Ilumetri® (tildrakizumab) demonstrates high rates of skin clearance and sustained wellbeing restoration in Adults with Moderate-to-Severe Plaque Psoriasis to general population levels for up to one year (1) Thu, 04 Jul 2024 12:00:00 +0200 https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almiralls-ilumetri-r-tildrakizumab-demonstrates-high-rates-of-skin-clearance-and-sustained-wellbeing-restoration-in-adults-with-moderate-to-severe-plaque-psoriasis-to-general-population-levels-for-up-to-one-year-1-3333539?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almiralls-ilumetri-r-tildrakizumab-demonstrates-high-rates-of-skin-clearance-and-sustained-wellbeing-restoration-in-adults-with-moderate-to-severe-plaque-psoriasis-to-general-population-levels-for-up-to-one-year-1-3333539?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB EBGLYSS® (lebrikizumab) er ny førsteplasserte interleukin-hemmere for alvorlig atopisk dermatitt hos voksne og ungdom på TNF BIO 2406b fra 1. mai 2024 (1,2) Tue, 28 May 2024 08:00:00 +0200 https://www.mynewsdesk.com/no/almirall-ab/pressreleases/ebglyss-r-lebrikizumab-er-ny-foersteplasserte-interleukin-hemmere-for-alvorlig-atopisk-dermatitt-hos-voksne-og-ungdom-paa-tnf-bio-2406b-fra-1-mai-2024-12-3324969?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/pressreleases/ebglyss-r-lebrikizumab-er-ny-foersteplasserte-interleukin-hemmere-for-alvorlig-atopisk-dermatitt-hos-voksne-og-ungdom-paa-tnf-bio-2406b-fra-1-mai-2024-12-3324969?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB Almirall initiates first phase I clinical study of ALM223, an interleukin 2 mutant fusion protein for autoimmune diseases Thu, 21 Dec 2023 00:00:00 +0100 https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-initiates-first-phase-i-clinical-study-of-alm223-an-interleukin-2-mutant-fusion-protein-for-autoimmune-diseases-3301211?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-initiates-first-phase-i-clinical-study-of-alm223-an-interleukin-2-mutant-fusion-protein-for-autoimmune-diseases-3301211?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology Tue, 12 Dec 2023 00:00:00 +0100 https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-and-etherna-enter-into-a-multi-target-alliance-to-develop-mrna-based-therapies-in-medical-dermatology-3301208?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-and-etherna-enter-into-a-multi-target-alliance-to-develop-mrna-based-therapies-in-medical-dermatology-3301208?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases Tue, 14 Nov 2023 00:00:00 +0100 https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-and-absci-announce-ai-drug-discovery-partnership-to-rapidly-develop-novel-treatments-for-dermatological-diseases-3301206?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/no/almirall-ab/pressreleases/almirall-and-absci-announce-ai-drug-discovery-partnership-to-rapidly-develop-novel-treatments-for-dermatological-diseases-3301206?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Almirall AB